- Home
- ERNA
as 04-25-2025 4:00pm EST
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 14.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 207.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.15 - $2.63 | Next Earning Date: | 05-13-2025 |
| Revenue: | $582,000 | Revenue Growth: | 755.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Eterna Therapeutics Inc. (ERNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cherington Charles | ERNA | 10% Owner | Apr 2 '25 | Buy | $0.10 | 3,768,397 | $394,174.33 | 20,401,602 |
Latest Eterna Therapeutics Inc. News
ERNA Breaking Stock News: Dive into ERNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
MT Newswires
24 days ago
Eterna Therapeutics Insider Bought Shares Worth $394,174, According to a Recent SEC Filing
GlobeNewswire
25 days ago
Ernexa Therapeutics Closes New Funding Round
GlobeNewswire
a month ago
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
GlobeNewswire
2 months ago
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
TipRanks
3 months ago
Eterna appoints Zeldis, Sather to scientific advisory board
GlobeNewswire
3 months ago
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
MT Newswires
3 months ago
Top Midday Gainers
Compare ERNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ERNA Eterna Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.